Table 4.
Main results of meta-analyses subgroups.
| Luteinizing hormone (LH) + follicle-stimulating hormone (FSH) vs. FSH | Human chorionic gonadotropin (hCG) + FSH vs. FSH | Human menopausal gonadotropin (hMG) vs. FSH | LH + FSH vs. hCG + FSH | |
|---|---|---|---|---|
| Oocytes retrieved (mean difference) | ||||
| Overall analysis | −0.20 (−0.36, −0.04) | 0.24 (−2.27, 2.75) | −0.92 (−1.45, −0.39) | 0.39 (−0.83, 1.61) |
| p = 0.01 | p = 0.850 | p < 0.001 | p = 0.530 | |
| I2 = 88% | I2 = 99% | I2 = 94% | I2 = 96% | |
| 29 studies | 7 studies | 20 studies | 5 studies | |
| 5,840 patients | 948 patients | 5,512 patients | 538 patients | |
| Gonadotropin-releasing hormone (GnRH) agonist | −0.35 (−0.63, −0.08) | – | −0.43 (−0.95, 0.10) | – |
| p = 0.01 | p = 0.11 | |||
| I2 = 93% | I2 = 93% | |||
| 17 studies | 16 studies | |||
| 3,677 patients | 3,347 patients | |||
| GnRH antagonist | 0.01 (−0.13, 0.16) | – | −2.38 (−3.10, −1.66) | – |
| p = 0.840 | p < 0.001 | |||
| I2 = 54% | I2 = 42% | |||
| 10 studies | 4 studies | |||
| 2,163 patients | 2,165 patients | |||
| FSH/oocytes (mean difference) | ||||
| Overall analysis | −0.16 (−0.21, −0.11) | −0.04 (−0.17, 0.09) | 0.17 (0.11, 0.23) | −0.25 (−0.94, 0.44) |
| p < 0.001 | p = 0.550 | p < 0.001 | p = 0.480 | |
| I2 = 92% | I2 = 84% | I2 = 86% | I2 = 90% | |
| 26 studies | 6 studies | 15 studies | 4 studies | |
| 5,404 patients | 893 patients | 4,436 patients | 382 patients | |
| GnRH agonist | −0.06 (−0.13, 0.01) | – | 0.07 (−0.01, 0.14) | – |
| p = 0.080 | p = 0.090 | |||
| I2 = 90% | I2 = 84% | |||
| 18 studies | 12 studies | |||
| 3,613 patients | 2,900 patients | |||
| GnRH antagonist | −0.36 (−0.45, −0.26) | – | 0.35 (0.25, 0.45) | – |
| p < 0.001 | p < 0.001 | |||
| I2 = 95% | I2 = 74% | |||
| 8 studies | 3 studies | |||
| 1,791 patients | 1,536 patients | |||
| MII oocytes (mean difference) | ||||
| Overall analysis | −0.27 (−0.56, 0.02) | −0.37 (−2.45, 1.71) | −0.60 (−1.31, 0.12) | −0.54 (−1.13, 0.05) |
| p = 0.07 | p = 0.730 | p = 0.10 | p = 0.07 | |
| I2 = 94% | I2 = 91% | I2 = 89% | I2 = 92% | |
| 20 studies | 5 studies | 11 studies | 4 studies | |
| 3,544 patients | 352 patients | 2,871 patients | 424 patients | |
| GnRH agonist | −0.50 (−1.01, 0.01) | – | 0.15 (−1.30, 1.60) | – |
| p = 0.05 | p = 0.84 | |||
| I2 = 96% | I2 = 86% | |||
| 13 studies | 7 studies | |||
| 1,915 patients | 706 patients | |||
| GnRH antagonist | 0.04 (−0.08, 0.15) | – | −1.36 (−1.51, −1.21) | – |
| p = 0.54 | p < 0.001 | |||
| I2 = 17% | I2 = 0% | |||
| 7 studies | 4 studies | |||
| 1,629 patients | 2,165 patients | |||
| Embryos (mean difference) | ||||
| Overall analysis | −0.04 (−0.17, 0.10) | 0.07 (−0.39, 0.53) | 0.19 (0.07, 0.30) | −0.12 (−0.19, −0.06) |
| p = 0.54 | p = 0.77 | p = 0.001 | p < 0.001 | |
| I2 = 83% | I2 = 74% | I2 = 94% | I2 = 83% | |
| 26 studies | 7 studies | 16 studies | 4 studies | |
| 4,721 patients | 918 patients | 3,321 patients | 500 patients | |
| GnRH agonist | −0.07 (−0.25, 0.11) | – | 0.23 (0.10, 0.35) | – |
| p = 0.43 | p < 0.001 | |||
| I2 = 88% | I2 = 95% | |||
| 17 studies | 13 studies | |||
| 2,890 patients | 2,589 patients | |||
| GnRH antagonist | 0.03 (−0.11, 0.18) | – | −0.02 (−0.19, 0.16) | – |
| p = 0.64 | p = 0.86 | |||
| I2 = 36% | I2 = 74% | |||
| 9 studies | 3 studies | |||
| 1,831 patients | 732 patients | |||
| Implantation rate (mean difference) | ||||
| Overall analysis | 0.11 (0.00, 0.21) | −0.06 (−0.03, 0.01) | 0.22 (0.02, 0.23) | −0.00 (−0.16, 0.15) |
| p = 0.05 | p = 0.59 | p = 0.03 | p = 0.98 | |
| I2 = 99% | I2 = 0% | I2 = 100% | I2 = 96% | |
| 15 studies | 5 studies | 10 studies | 4 studies | |
| 2,669 patients | 749 patients | 3,208 patients | 430 patients | |
| GnRH agonist | 0.16 (0.00, 0.31) | – | 0.25 (−0.01, 0.51) | – |
| p = 0.05 | p = 0.06 | |||
| I2 = 100% | I2 = 100% | |||
| 10 studies | 8 studies | |||
| 1,256 patients | 2,299 patients | |||
| GnRH antagonist | 0.01 (−0.08, 0.10) | – | 0.15 (0.13, 0.17) | – |
| p = 0.83 | p < 0.001 | |||
| I2 = 85% | I2 = 0% | |||
| 6 studies | 2 studies | |||
| 1,393 patients | 909 patients | |||
| Pregnancy rate (odds ratio) | ||||
| Overall analysis | 1.20 (1.06, 1.37) | 0.96 (0.72, 1.26) | 1.10 (0.98, 1.22) | 1.73 (1.26, 2.38) |
| p = 0.004 | p = 0.750 | p = 0.100 | p < 0.001 | |
| I2 = 5% | I2 = 0% | I2 = 0% | I2 = 48% | |
| 29 studies | 8 studies | 25 studies | 5 studies | |
| 5,665 patients | 968 patients | 6,894 patients | 989 patients | |
| GnRH agonist | 1.27 (1.09, 1.48) | – | 1.17 (1.01, 1.36) | – |
| p = 0.002 | p = 0.030 | |||
| I2 = 9% | I2 = 0% | |||
| 22 studies | 17 studies | |||
| 3,834 patients | 3,627 patients | |||
| GnRH antagonist | 1.08 (0.87, 1.35) | – | 1.10 (0.90, 1.34) | – |
| p = 0.480 | p = 0.370 | |||
| I2 = 0% | I2 = 0% | |||
| 9 studies | 4 studies | |||
| 1,831 patients | 2,165 patients | |||
| Live birth rate (odds ratio) | ||||
| Overall analysis | 1.29 (0.91, 1.84) | – | 1.13 (0.95, 1.33) | – |
| p = 0.15 | p = 0.17 | |||
| I2 = 45% | I2 = 10% | |||
| 5 studies | – | 7 studies | – | |
| 164 patients | 747 patients | |||
Bold character indicates significant results.